NIHR BRC-Respiratory, University of Leicester, Leicester, England, UK.
Department of Neurology and Neurosurgery, Structural Genomics Consortium, The Montreal Neurological Institute, McGill University, Montreal, Québec, H3A 2B4, Canada.
F1000Res. 2024 Jul 19;13:817. doi: 10.12688/f1000research.154034.1. eCollection 2024.
Synaptotagmin-1 is a synaptic vesicle transmembrane protein that senses calcium influx via its tandem C2-domains, triggering synchronous neurotransmitter release. Disruption to is associated with neurodevelopmental disorders, highlighting the importance of identifying high-quality research reagents to enhance understanding of Synaptotagmin-1 in health and disease. Here we have characterized thirteen Synaptotagmin-1 commercial antibodies for western blot, immunoprecipitation, immunofluorescence and flow cytometry using a standardized experimental protocol based on comparing read-outs in knockout cell lines and isogenic parental controls. These studies are part of a larger, collaborative initiative seeking to address antibody reproducibility issues by characterizing commercially available antibodies for human proteins and publishing the results openly as a resource for the scientific community. While use of antibodies and protocols vary between laboratories, we encourage readers to use this report as a guide to select the most appropriate antibodies for their specific needs.
突触融合蛋白 1 是一种突触小泡跨膜蛋白，通过其串联的 C2 结构域感知钙内流，触发同步神经递质释放。的破坏与神经发育障碍有关，这凸显了识别高质量研究试剂的重要性，以增强对突触融合蛋白 1 在健康和疾病中的理解。在这里，我们使用基于比较敲除细胞系和同基因亲本对照的读出值的标准化实验方案，对 13 种突触融合蛋白 1 商业抗体进行了 Western blot、免疫沉淀、免疫荧光和流式细胞术的表征。这些研究是一项更大的合作计划的一部分，该计划旨在通过对人类蛋白质的商业抗体进行表征，并将结果公开作为科学界的资源来解决抗体重现性问题。虽然不同实验室使用的抗体和方案有所不同，但我们鼓励读者将本报告用作指南，根据自己的具体需求选择最合适的抗体。
